To include your compound in the COVID-19 Resource Center, submit it here.

Emisphere deal

Sandoz Pharmaceuticals decided not to develop EMIS's oral delivery system for calcitonin, despite a joint feasibility study that

Read the full 183 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE